Wedbush cuts Denali target to USD 23 for Denali Therapeutics stock
Published on 10/24/2026 at 20:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Wedbush cut its Denali target from USD 27.00 to USD 23.00 on October 19, 2026.
- Denali will report third-quarter 2026 results on November 3, 2026.
- Denali Therapeutics stock costs EUR 16.43 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Denali Therapeutics (ISIN US24823R1059) is heading toward its next results date after Yahoo Finance reported on October 19, 2026 that Wedbush cut its price target from USD 27.00 to USD 23.00 while keeping an Outperform rating. GlobeNewswire reported on October 22, 2026 that the company will publish third-quarter results and business highlights on November 3, 2026. Denali stock was trading at EUR 16.43 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Target cut sets the analyst tone
The Wedbush reduction leaves the new target USD 4.00 below the previous USD 27.00 level. The firm nevertheless retained its Outperform rating, making the target revision less negative than a simultaneous rating downgrade.
The broader analyst picture remains higher than Wedbush's revised target. MarketBeat listed a consensus target of USD 35.85 from 16 analysts and an expected third-quarter revenue figure of USD 12.22 million.
Results date brings a measurable test
Denali's November 3 release covers the quarter ended September 30, 2026. The company scheduled its conference call for 4:30 p.m. ET on the same date, giving investors a defined point for checking revenue progress and business updates.
MarketBeat's estimate compares with USD 3.60 million of revenue in the second quarter of 2026. That sequential comparison places the expected third-quarter figure USD 8.62 million higher than the prior quarter, although the estimate remains subject to the reported result.
Price position and company profile
Denali's Nasdaq quote was USD 18.41 on October 23, 2026, while its 52-week range was USD 13.75 to USD 27.30. Its market capitalization was USD 2.9 billion on that date, and the stock traded 39.74 percent below its 52-week high.
The company identifies itself as a biotechnology business developing therapies designed to cross the blood-brain barrier. Its investor materials state that Denali is listed on the Nasdaq Global Select Stock Market under the ticker DNLI and that fiscal year-end is December 31.
Comparison with peers
Denali Therapeutics: minus 1.34 percent on October 23, 2026, market capitalization USD 2.9 billion.
Sarepta Therapeutics (NASDAQ, USD): minus 2.48 percent on October 23, 2026, market capitalization USD 1.9 billion.
Ionis Pharmaceuticals (NASDAQ, USD): minus 2.23 percent on October 23, 2026, market capitalization USD 7.1 billion.
What comes next for Denali
The November 3 report is the next dated corporate event, while the revised Wedbush target gives the market a lower analyst benchmark than the earlier USD 27.00 level. The combination leaves the reported quarter and the company's business update as the next concrete tests for the valuation.
The further course of trading is shown by the continuously updated real-time quote of Denali Therapeutics stock.
Denali Therapeutics key data
- Company: Denali Therapeutics Inc.
- ISIN: US24823R1059
- Ticker: DNLI
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 24, 2026, 1:04 p.m. CEST): EUR 16.43
- Market capitalization: USD 2.9 billion (as of October 23, 2026)
- 52-week range: USD 13.75-27.30 (as of October 23, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
